NPS Pharma (NPSP) Halted Ahead of FDA Committee Meeting for Gattex
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Join SI Premium – FREE
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) shares were halted ahead of the Gastrointestinal Drugs Advisory Committee meeting to review Gattex (teduglutide). The meeting is scheduled for today, October 16, 2012 at 8:00 a.m. ET.
The briefing materials can be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/ucm291609.htm. The Prescription Drug User Fee Act date for completion of the review of the company’s New Drug Application for Gattex is December 30, 2012.
The briefing materials can be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/ucm291609.htm. The Prescription Drug User Fee Act date for completion of the review of the company’s New Drug Application for Gattex is December 30, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfpack Research: 'we are short FTK because their $400m deal has been canceled'
- NVIDIA to invest $100bn for OpenAI data centre in Ohio - FT
- Buss family to sell rest of Lakers stake to Kushner, Iger - ESPN
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
